Citius Oncology - CTOR Operating profit EBITDA
Citius Oncology, Inc. (CTOR) is accelerating drug development through AI and robotics to remain competitive in the fierce battle for capital within the biotech sector. The company's consolidated EBITDA on this chart demonstrates the business's actual trajectory, with the metric currently standing at 0.00. Future share price growth depends on the successful implementation of the drug Lymphir and the control of operational marketing expenses.
Citius Oncology (CTOR) - metric breakdowns and financial figures
- current quotes and average value forecast:
- issuer market value details:
- book value of equity indicators:
- debt level and financial liquidity data:
Total Debt to Equity Ratio Citius Oncology, Inc.|CTOR - Long-Term Debt to Capital|Short-Term Debt to Capital Coefficient Citius Oncology Inc.|CTOR - Company Total Debt|Debt to Book Capital Citius Oncology|CTOR - Company Long-Term Debts|Short-Term Debt Volume Citius Oncology|Quick Ratio citiusonc.com
- earnings and market ratios statistics:
CTOR - Company Net Income|Company Profit Forecast Citius Oncology, Inc.|CTOR - Price to Earnings Ratio|Future Price to Earnings Multiple citiusonc.com|CTOR - Price/Earnings to Growth Ratio|Company Value to EBITDA Citius Oncology|CTOR - Profit before payment of interest, taxes and amortization|Earnings per share for the last 12 months Citius Oncology|CTOR - Net earnings per share (EPS TTM)|Year-over-year net earnings per share growth for the last 12 months citiusonc.com|CTOR - Earnings per share growth in current year|Expected net earnings per share growth next year Citius Oncology, Inc.
Fundamental company valuation:Citius Oncology Inc CTOR
A conservative investor assesses the fundamental stability of Citius Oncology, Inc. (CTOR) through the lens of the business's ability to generate real cash flow. Analyzing EBITDA fluctuations on the GURU.Markets platform, you can see the operating profit before interest and taxes, which reflects the funding efficiency for elite oncologists and the cost of developing targeted drugs, thereby determining the asset's current investment attractiveness.
Who Citius Oncology, Inc. competes with
ONC - Operating profit before deduction of amortization|HALO: Operating profit before deduction of amortization|RVMD - Operating profit EBITDA|Ascentage Pharma (AAPG) - Profit before payment of interest, taxes and amortization|CG Oncology Inc - Income before deduction of interest, taxes and amortization|URGN (UroGen) - Operating profit EBITDA|Profit before interest, taxes and amortization Bicara Corp BCAX|Operating profit EBITDA PSNL|Operating profit before deduction of amortization erasca.com ERAS|Operating profit EBITDA DCTH (Delcath Systems)|Operating income before deduction of amortization Y-mAbs Therapeutics Inc (YMAB)|AURA: Operating profit before deduction of amortization|Candel Therapeutics - Company profit before taxes, interest and amortization|ARAY: Operating profit EBITDA|SLS - Operating income before deduction of amortization|Operating profit before deduction of amortization ACTU|Operating profit EBITDA TuHURA|Profit before payment of interest, taxes and amortization Protara (TARA)|Operating income before deduction of amortization Fate Pharma|Aadi Bioscience - Operating profit before deduction of amortization|Income before deduction of interest, taxes and amortization TCRX|CSBR - Profit before payment of interest, taxes and amortization|Profit before interest, taxes and amortization XBiotech Inc.|cel-sci.com (CVM) - Profit before payment of interest, taxes and amortization|Operating profit before amortization OSTX|RADX (Radiopharm Theranostics) - Operating profit EBITDA|Operating profit before deduction of amortization Artiva (ARTV)|Profit before payment of interest, taxes and amortization Adlai Nortye Ltd. (ANL)|VERU - Profit before interest, taxes and amortization|Profit before payment of interest, taxes and amortization Tempest Tx TPST|Xilio Therapeutics Inc - Profit before payment of interest, taxes and amortization|RENB - Profit before payment of interest, taxes and amortization|Profit before interest, taxes and amortization Mural Oncology plc|KAPA: Operating profit EBITDA|Operating profit before depreciation charges OnKure Therapeutics OKUR|Operating profit before deduction of amortization GDTC|Profit before interest, taxes and amortization Curis Corp CRIS|Operating profit before deduction of amortization APLM (Apollomics, Inc.)|THAR (tharimmune.com) - Income before deduction of interest, taxes and amortization|Operating profit EBITDA ADVB (Advanced Biomed)|Operating income before deduction of amortization Genprex Inc. (GNPX)|CLDI - Profit before payment of interest, taxes and amortization|SBFM (sunshinebiopharma.com) - Operating profit before amortization|XBIO: Operating profit EBITDA|Operating profit before deduction of amortization salariuspharma.com|Operating profit before deduction of amortization PPBT|AON (AONC) - Operating income before deduction of amortization|Operating profit EBITDA BGNE|Operating profit before deduction of amortization Checkpoint Therapeutics Inc CKPT|Elevation Oncology - Operating profit before deduction of amortization|Company profit before taxes, interest and amortization ICAD (iCAD Inc.)|IKNA - Profit before payment of interest, taxes and amortization|Profit before interest, taxes and amortization Notable Labs Ltd|viracta.com (VIRX) - Profit before payment of interest, taxes and amortization|MorphoSys Corporation - Income before deduction of interest, taxes and amortization|NAYA (NAYA Biosciences) - Operating profit EBITDA|Operating profit before deduction of amortization ascentage.com (AAPGV)
